ArticleAntibiotics (Basel, Switzerland)2021
Effect of Imipenem and Amikacin Combination against Multi-Drug Resistant
Article in Antibiotics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 28 citations in OpenAlex.
- Surface charge-dependent effects of BSA-curcumin nanoparticles combined with amikacin in antimicrobial photodynamic therapy: A pilot In Vivo study of multidrug-resistant Pseudomonas aeruginosa skin infection.Lasers in medical science · 2026Article
- In Vitro Antibacterial Effect of Probiotics Against Bacterial Isolates from Diabetic Foot Ulcers in Ain Shams University Hospitals.Probiotics and antimicrobial proteins · 2026Article
- Study of the Impact of Antibiotic Combinations Used in Urinary Tract Infections on the Effectiveness of Antimicrobial Therapy.Journal of clinical medicine · 2026Article
- Synergistic Inhibition ofMicroorganisms · 2026Article
- Synergistic effects of meropenem, amikacin, and ciprofloxacin against carbapenem resistant Pseudomonas aeruginosa isolates.Scientific reports · 2026Article
- Occurrence of Virulence and Antibiotic Resistance inAntibiotics (Basel, Switzerland) · 2025Article
- A Retrospective Study on the Prevalence and Antimicrobial Susceptibility of Gram-Positive Cocci in a Pediatric Department: A Single-Center Report from Egypt.Medicina (Kaunas, Lithuania) · 2025Article
- The Efficacy and Tolerability of Colistin Versus Non-Colistin Antimicrobial Regimens Among Hospitalized COVID-19 Patients with Multidrug-Resistant Bacterial Superinfection: An Observational Multicenter Study.Medicina (Kaunas, Lithuania) · 2025Observational
- RETRACTED: The effect of biosynthesized silver nanoparticles on Pseudomonas aeruginosa-infected dogs wounds.PloS one · 2025Article
- Investigation of in vitro susceptibility and resistance mechanisms to amikacin among diverse carbapenemase-producing Enterobacteriaceae.BMC medical genomics · 2024Article
- Comparative Investigation into the Roles of Imipenem:Cyclodextrin Complexation and Antibiotic Combination in Combatting Antimicrobial Resistance in Gram-Negative Bacteria.Pharmaceuticals (Basel, Switzerland) · 2023Article
- The comparative effects of erythromycin and amikacin on acute respiratory Pseudomonas aeruginosa infection.Veterinary medicine and science · 2023Article
- Emergence of NDM-1-producingAnnals of laboratory medicine · 2023Article
- Evidence-Based Treatment ofAntibiotics (Basel, Switzerland) · 2023Review
- Metabolomics reveals the mechanism of action of meropenem and amikacin combined in the treatment ofFrontiers in cellular and infection microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.